David Reichstein, MD
Retina Specialist · Nashville, TNNPI 1669665105
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 44.4% of the total. Among retina specialist clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $390.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$51K
- Regeneron Healthcare Solutions, Inc.$33K
- US Retina LLC$17K
- Carl Zeiss Meditec, Inc.$4K
- Immunocore Limited$4K
- Alimera Sciences, Inc.$3K
- plus $4K from 14 others
Across 135 payments — averaging $455.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$55K
- Mylan Technologies Inc.$6K
- Mylan Inc.$95
What the payments were for
- Consulting fees$17,65315%
- Speaking & faculty fees$57,35450%
- Travel & lodging$9,4738%
- Food & beverage$13,17312%
- Ownership interest$7,2626%
- Other$9,5028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 95 | $50,777 |
| Regeneron Healthcare Solutions, Inc. | 50 | $32,781 |
| US Retina LLC | 7 | $16,764 |
| Carl Zeiss Meditec, Inc. | 1 | $4,000 |
| Immunocore Limited | 18 | $3,868 |
| Alimera Sciences, Inc. | 42 | $2,565 |
| Regeneron | 7 | $453 |
| AbbVie(2 entities) | 14 | $452 |
| Genentech, Inc. | 6 | $410 |
| Harrow Eye, LLC | 6 | $401 |
| Astellas Pharma US Inc | 12 | $370 |
| Alcon | 4 | $349 |
| Delcath Systems | 3 | $277 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $233 |
| Apellis Pharmaceuticals, Inc. | 8 | $204 |
| Coherus Oncology, Inc. | 4 | $198 |
| Biogen | 7 | $161 |
| Novartis | 4 | $106 |
| Amgen | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,417 in reported general payments places this provider in the 90th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 279 | $13,226 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $4,320 |
| Brimonidine Tartrate | 59 | $2,704 |
| Atropine Sulfate | 64 | $2,254 |
| Latanoprost | 198 | $1,999 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 32 | $1,657 |
| Ketorolac Tromethamine | 68 | $1,214 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 83 | $1,000 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 84 | $751 |
| Timolol Maleate | 67 | $483 |
| ErythromycinErythromycin Base | 46 | $438 |
| Ciprofloxacin Hcl | 25 | $420 |
| Dorzolamide Hcl | 23 | $384 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 50 | $342 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $452 | $4,32015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 58 retina specialist providers in Tennessee.
Other retina specialist in Nashville
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- Akshay ThomasNashville$108K
- Franco RecchiaNashville$72K
- Everton ArrindellNashville$39K
- Roy WallaceNashville$19K
- Kenneth MoffatNashville$17K
- Brigid MarshallNashville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.